Not Agreed

[]

f 1

Agreed

[]

f 1

Doc Code: M865 or FALREQ.INTV

Claims/

17-35

Fig. #s

Issues

(Rej., Obj., etc)

(1)_102/103/

112 Rejections

| | 0.0.1 | alistic and Trademark Office, 6.5, DET ARTIMENT OF COMMERCE |
|---|--|---|
| Applicant | Initiated Interview | Request Form |
| Application No.: 10/528,928 Examiner: Chang-Yu Wang | First Named Applicant; Art Unit: 1649 | Mercken, MH Status of Application: pending |
| Tentative Participants: (1) Andrea Kamage | (2) Yu-Ming Dam | nann |
| (3) Jeffrey Stucker | (4) | |
| Proposed Date of Interview: March | 1, 2010 | Proposed Time: 1:30PM (AM/PM) |
| Type of Interview Requested: (1) [격 Telephonie (2) [Persona | d (3) [] Video C | onference |
| Exhibit To Be Shown or Demonstrate If yes, provide brief description: <u>Tab</u> | | []NO |

Issues To Be Discussed

Prior Art Discussed

٢1

f 1

| (3) | [] | [] | [] |
|---|-------------------------------------|-------------------|--|
| (4) [] Continuation Sheet Attached [] Proposed Amendment or Arguments Attached Brief Description of Arguments to be Presented: | [] | [] | [] |
| 1. Review differences between claimed | antibodi | es and pri | or-art |
| antibodies, and, 2. additional referen | ces | | |
| | | | |
| NOTE: This form should be completed by applicant and sub (see MPEP § 713.01). This application will not be delayed from issue because of app interview. Therefore, applicant is advised to file a statement of as soon as possible. Applicant/Applicant's Representative Signature | licant's failure f the substance | to submit a writt | en record of this (37 CFR 1.133(b)) |

The collection of Information is required by 37 CFR L133. The Information is required to obtain or credit in benefit by one public which is offic (and by recombination) of the public confidentially is governed by 38 LSC L22 and 37 CFR L130 and 14. This colorism is estimated to task? In admires to complete, Including gathering, preparing, and submitting the completed application form to the USF10. These will vary depending upon the individual case. Any comments on the amount of time, your require to complete the form and/or supercustas for reducing this burden, should be sent to the CSF10. The will be burden, should be sent to the CSF10. The comments of USF10 and the sent to the CSF10 and the complete of USF10 and the CSF10 and the CSF